PureWick™ France and U.S. At-Home Pilot Study

Nocturnal Enuresis Clinical Trial

Official title:

A Comparative Crossover Study on the Safety, Efficacy, and Patient Quality of Life Comparing PureWick™ System With an Established Comparator in the Home Setting for Incontinence Overnight

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05710718
• Other study ID #: UCC-8007
• Status: Enrolling by invitation
• Phase: N/A
• Start date: October 31, 2023
• Est. completion date: May 9, 2024

Study information

• Verified date: December 2023
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence using two devices (PureWick™ System and Hollister® Female Urinary Pouch External Collection Device) and followed for approximately 10 weeks through 2 treatment phases. The primary objectives are to evaluate safety (skin injury) and efficacy (capture rate). Safety will be assessed using the Draize Scale and efficacy will be measured based on daily urine capture rate.

Description:

In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence using two devices (PureWick™ System and Hollister® Female Urinary Pouch External Collection Device) and followed for approximately 10 weeks through 2 treatment phases.

Approximately 30 female participants from 2 sites will be enrolled into the study. Those meeting eligibility criteria will be treated according to the treatment sequence assigned during randomization. Participants will view the standardized training video for the applicable product at the beginning of each treatment phase and have access to the Information for Use document (IFU) to review during each treatment phase. The total expected duration of subject participation is approximately 10 weeks. Participants will use the device assigned in treatment phase 1 overnight while sleeping for 4 weeks (28 days) before transitioning to the second assigned device in treatment phase 2. There will be a minimum washout period of 2 weeks (not to exceed 4 weeks) between treatment phases and a re-screening of eligibility criteria before the second phase. In both treatment phases, participants will independently place and remove the FEC (female external catheter) or FUP (Female Urinary Pouch) after standardized teaching is completed on the first day of the treatment phase.

The primary objectives are to evaluate safety (skin injury) and efficacy (capture rate). Safety will be assessed using the Draize Scale and efficacy will be measured based on daily urine capture rate. Health Care Providers (HCPs) will visit participants' homes daily to perform a skin assessment and collect urine measurements during the treatment phases. Participants will be withdrawn from the treatment phase if grade 4 is achieved in any category on the Draize skin irritation scale.

The secondary objectives are to assess quality of life, tolerability, comfort and ease of use. Quality of life and comfort and ease of use will be measured using self-reported changes in quality of life via the validated Nocturia Quality of Life (N-Qol) tool and subjective evaluation of the therapy via participant survey, respectively. Tolerability will be measured by number of days of actual use of both devices, and discontinuation rate attributed to the device's discomfort or inconvenience.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 30
• Est. completion date: May 9, 2024
• Est. primary completion date: May 9, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult Female Participants >18 years of age at the time of signing the informed consent.

2. Currently use diapers or equivalent at night for urine capture ("Change complet"(French term))

3. Willing to comply with all study procedures in this protocol

4. Provision of signed and dated informed consent form

Exclusion Criteria:

1. Has frequent episodes of bowel incontinence without a fecal management system in place; or

2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or

3. Has Urinary tract, vaginal or other chronic infections, active genital herpes; or

4. Has Urinary retention; or

5. Is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or

6. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or

7. Has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or

8. Is known to be pregnant at time of enrollment (for women of childbearing age); or

9. Any other condition that, in the opinion of the investigator, would preclude them from participating in the study.

10. Is under supervision of a legally authorized representative.

Related Conditions & MeSH terms

• Enuresis
• Nocturnal Enuresis

Intervention

Device:
• PureWick™ System
The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC will be connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
• Hollister® Female Urinary Pouch External Collection Device
It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.

Locations

Country	Name	City	State
France	CHU d'Angers, Universite d'Angers	Angers
France	Centre Hospitalier Universitaire de Lille	Lille
United States	Smiths Medical Center	Dunwoody	Georgia
United States	Weill Cornell Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Daily urine capture rate (percentage)	Urine weight captured in the device divided by the sum of urine weight captured in the device plus the leaked urine weight	Daily for 29 days during each treatment phase
Primary	Daily skin irritation score using the Draize Scale	Draize Scale is a 5 point scale where 0 is no erythema, edema, or bleeding and 4 is severe erythema, edema, and/or bleeding.	Daily for 29 days during each treatment phase
Secondary	Nocturia Quality of Life (N-QOL) score	N-QOL is a standardized tool used to explore 13 items that might be affected by nocturia (e.g., concentration, productiveness, and low energy	Starting at baseline and then every 2 weeks during each treatment phase
Secondary	Participant's tolerability of device/treatment	Participant's tolerability will be determined by the number of days of actual use of both devices and the discontinuation rate attributed to the device's inconvenience to the participants.	Daily for 29 days during each treatment phase or until end of device use for each treatment phase
Secondary	Participant's comfort level associated with device/treatment	Overall comfort will determine by having the participants complete a survey with scores on a 5-point Likert scale collected at the end of each treatment phase	Daily use of for 29 days during each treatment phase and one survey collected at the end of each treatment phase
Secondary	Participant's opinion of ease of device/treament	Overall ease of use will determine by having the participants complete a survey with scores on a 5-point Likert scale collected at the end of each treatment phase.	Daily use of for 29 days during each treatment phase and one survey collected at the end of each treatment phase